+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Breast Cancer Monoclonal Antibodies Market 2023-2027

  • PDF Icon

    Report

  • 173 Pages
  • July 2023
  • Region: Global
  • TechNavio
  • ID: 5868268
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The breast cancer monoclonal antibodies market is forecasted to grow by USD 15 bn during 2022-2027, accelerating at a CAGR of 12.5% during the forecast period. The report on the breast cancer monoclonal antibodies market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of breast cancer, rising number of patient support initiatives for breast cancer awareness, and increasing demand for minimally invasive therapies for breast cancer treatment.

The breast cancer monoclonal antibodies market is segmented as below:

By End-user

  • Hospitals
  • Research institutes
  • Others

By Type

  • Humanized
  • Human
  • Chimeric
  • Murine

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the increase in number of product approvals and expanded product pipeline as one of the prime reasons driving the breast cancer monoclonal antibodies market growth during the next few years. Also, growing number of strategic collaborations and increasing focus on breast cancer diagnosis and treatment in emerging economies will lead to sizable demand in the market.

The report on the breast cancer monoclonal antibodies market covers the following areas:

  • Breast cancer monoclonal antibodies market sizing
  • Breast cancer monoclonal antibodies market forecast
  • Breast cancer monoclonal antibodies market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading breast cancer monoclonal antibodies market vendors that include Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celldex Therapeutics Inc., Celltrion Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Johnson and Johnson Services Inc., MacroGenics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Sanofi, Seagen Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the breast cancer monoclonal antibodies market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by End-user
Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
4.1 Global breast cancer monoclonal antibodies market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on global breast cancer monoclonal antibodies market 2017 - 2021 ($ billion)
4.2 End-user Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - End-user Segment 2017 - 2021 ($ billion)
4.3 Type Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Type Segment 2017 - 2021 ($ billion)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ billion)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ billion)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by End-user
6.1 Market segments
Exhibit 30: Chart on End-user - Market share 2022-2027 (%)
Exhibit 31: Data Table on End-user - Market share 2022-2027 (%)
6.2 Comparison by End-user
Exhibit 32: Chart on Comparison by End-user
Exhibit 33: Data Table on Comparison by End-user
6.3 Hospitals - Market size and forecast 2022-2027
Exhibit 34: Chart on Hospitals - Market size and forecast 2022-2027 ($ billion)
Exhibit 35: Data Table on Hospitals - Market size and forecast 2022-2027 ($ billion)
Exhibit 36: Chart on Hospitals - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Hospitals - Year-over-year growth 2022-2027 (%)
6.4 Research institutes - Market size and forecast 2022-2027
Exhibit 38: Chart on Research institutes - Market size and forecast 2022-2027 ($ billion)
Exhibit 39: Data Table on Research institutes - Market size and forecast 2022-2027 ($ billion)
Exhibit 40: Chart on Research institutes - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Research institutes - Year-over-year growth 2022-2027 (%)
6.5 Others - Market size and forecast 2022-2027
Exhibit 42: Chart on Others - Market size and forecast 2022-2027 ($ billion)
Exhibit 43: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
Exhibit 44: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on Others - Year-over-year growth 2022-2027 (%)
6.6 Market opportunity by End-user
Exhibit 46: Market opportunity by End-user ($ billion)
Exhibit 47: Data Table on Market opportunity by End-user ($ billion)
7 Market Segmentation by Type
7.1 Market segments
Exhibit 48: Chart on Type - Market share 2022-2027 (%)
Exhibit 49: Data Table on Type - Market share 2022-2027 (%)
7.2 Comparison by Type
Exhibit 50: Chart on Comparison by Type
Exhibit 51: Data Table on Comparison by Type
7.3 Humanized - Market size and forecast 2022-2027
Exhibit 52: Chart on Humanized - Market size and forecast 2022-2027 ($ billion)
Exhibit 53: Data Table on Humanized - Market size and forecast 2022-2027 ($ billion)
Exhibit 54: Chart on Humanized - Year-over-year growth 2022-2027 (%)
Exhibit 55: Data Table on Humanized - Year-over-year growth 2022-2027 (%)
7.4 Human - Market size and forecast 2022-2027
Exhibit 56: Chart on Human - Market size and forecast 2022-2027 ($ billion)
Exhibit 57: Data Table on Human - Market size and forecast 2022-2027 ($ billion)
Exhibit 58: Chart on Human - Year-over-year growth 2022-2027 (%)
Exhibit 59: Data Table on Human - Year-over-year growth 2022-2027 (%)
7.5 Chimeric - Market size and forecast 2022-2027
Exhibit 60: Chart on Chimeric - Market size and forecast 2022-2027 ($ billion)
Exhibit 61: Data Table on Chimeric - Market size and forecast 2022-2027 ($ billion)
Exhibit 62: Chart on Chimeric - Year-over-year growth 2022-2027 (%)
Exhibit 63: Data Table on Chimeric - Year-over-year growth 2022-2027 (%)
7.6 Murine - Market size and forecast 2022-2027
Exhibit 64: Chart on Murine - Market size and forecast 2022-2027 ($ billion)
Exhibit 65: Data Table on Murine - Market size and forecast 2022-2027 ($ billion)
Exhibit 66: Chart on Murine - Year-over-year growth 2022-2027 (%)
Exhibit 67: Data Table on Murine - Year-over-year growth 2022-2027 (%)
7.7 Market opportunity by Type
Exhibit 68: Market opportunity by Type ($ billion)
Exhibit 69: Data Table on Market opportunity by Type ($ billion)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 71: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 72: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 73: Chart on Geographic comparison
Exhibit 74: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ billion)
Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ billion)
Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ billion)
Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 France - Market size and forecast 2022-2027
Exhibit 95: Chart on France - Market size and forecast 2022-2027 ($ billion)
Exhibit 96: Data Table on France - Market size and forecast 2022-2027 ($ billion)
Exhibit 97: Chart on France - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on France - Year-over-year growth 2022-2027 (%)
9.9 China - Market size and forecast 2022-2027
Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ billion)
Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ billion)
Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%)
9.10 The Netherlands - Market size and forecast 2022-2027
Exhibit 103: Chart on The Netherlands - Market size and forecast 2022-2027 ($ billion)
Exhibit 104: Data Table on The Netherlands - Market size and forecast 2022-2027 ($ billion)
Exhibit 105: Chart on The Netherlands - Year-over-year growth 2022-2027 (%)
Exhibit 106: Data Table on The Netherlands - Year-over-year growth 2022-2027 (%)
9.11 Canada - Market size and forecast 2022-2027
Exhibit 107: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
Exhibit 108: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
Exhibit 109: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 110: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 111: Market opportunity By Geographical Landscape ($ billion)
Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ billion)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 113: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 115: Overview on factors of disruption
11.4 Industry risks
Exhibit 116: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 117: Vendors covered
12.2 Market positioning of vendors
Exhibit 118: Matrix on vendor position and classification
12.3 Amgen Inc.
Exhibit 119: Amgen Inc. - Overview
Exhibit 120: Amgen Inc. - Product/Service
Exhibit 121: Amgen Inc. - Key offerings
12.4 AstraZeneca Plc
Exhibit 122: AstraZeneca Plc - Overview
Exhibit 123: AstraZeneca Plc - Product/Service
Exhibit 124: AstraZeneca Plc - Key news
Exhibit 125: AstraZeneca Plc - Key offerings
12.5 Boehringer Ingelheim International GmbH
Exhibit 126: Boehringer Ingelheim International GmbH - Overview
Exhibit 127: Boehringer Ingelheim International GmbH - Business segments
Exhibit 128: Boehringer Ingelheim International GmbH - Key news
Exhibit 129: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 130: Boehringer Ingelheim International GmbH - Segment focus
12.6 Bristol Myers Squibb Co.
Exhibit 131: Bristol Myers Squibb Co. - Overview
Exhibit 132: Bristol Myers Squibb Co. - Product/Service
Exhibit 133: Bristol Myers Squibb Co. - Key news
Exhibit 134: Bristol Myers Squibb Co. - Key offerings
12.7 Celldex Therapeutics Inc.
Exhibit 135: Celldex Therapeutics Inc. - Overview
Exhibit 136: Celldex Therapeutics Inc. - Product/Service
Exhibit 137: Celldex Therapeutics Inc. - Key offerings
12.8 Daiichi Sankyo Co. Ltd.
Exhibit 138: Daiichi Sankyo Co. Ltd. - Overview
Exhibit 139: Daiichi Sankyo Co. Ltd. - Product/Service
Exhibit 140: Daiichi Sankyo Co. Ltd. - Key news
Exhibit 141: Daiichi Sankyo Co. Ltd. - Key offerings
12.9 F. Hoffmann La Roche Ltd.
Exhibit 142: F. Hoffmann La Roche Ltd. - Overview
Exhibit 143: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 144: F. Hoffmann La Roche Ltd. - Key news
Exhibit 145: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 146: F. Hoffmann La Roche Ltd. - Segment focus
12.10 Gilead Sciences Inc.
Exhibit 147: Gilead Sciences Inc. - Overview
Exhibit 148: Gilead Sciences Inc. - Product/Service
Exhibit 149: Gilead Sciences Inc. - Key news
Exhibit 150: Gilead Sciences Inc. - Key offerings
12.11 Johnson and Johnson Services Inc.
Exhibit 151: Johnson and Johnson Services Inc. - Overview
Exhibit 152: Johnson and Johnson Services Inc. - Business segments
Exhibit 153: Johnson and Johnson Services Inc. - Key news
Exhibit 154: Johnson and Johnson Services Inc. - Key offerings
Exhibit 155: Johnson and Johnson Services Inc. - Segment focus
12.12 MacroGenics Inc.
Exhibit 156: MacroGenics Inc. - Overview
Exhibit 157: MacroGenics Inc. - Product/Service
Exhibit 158: MacroGenics Inc. - Key offerings
12.13 Merck KGaA
Exhibit 159: Merck KGaA - Overview
Exhibit 160: Merck KGaA - Business segments
Exhibit 161: Merck KGaA - Key news
Exhibit 162: Merck KGaA - Key offerings
Exhibit 163: Merck KGaA - Segment focus
12.14 Novartis AG
Exhibit 164: Novartis AG - Overview
Exhibit 165: Novartis AG - Business segments
Exhibit 166: Novartis AG - Key offerings
Exhibit 167: Novartis AG - Segment focus
12.15 Pfizer Inc.
Exhibit 168: Pfizer Inc. - Overview
Exhibit 169: Pfizer Inc. - Product/Service
Exhibit 170: Pfizer Inc. - Key news
Exhibit 171: Pfizer Inc. - Key offerings
12.16 Sanofi
Exhibit 172: Sanofi - Overview
Exhibit 173: Sanofi - Business segments
Exhibit 174: Sanofi - Key news
Exhibit 175: Sanofi - Key offerings
Exhibit 176: Sanofi - Segment focus
12.17 Viatris Inc.
Exhibit 177: Viatris Inc. - Overview
Exhibit 178: Viatris Inc. - Business segments
Exhibit 179: Viatris Inc. - Key news
Exhibit 180: Viatris Inc. - Key offerings
Exhibit 181: Viatris Inc. - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 182: Inclusions checklist
Exhibit 183: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 184: Currency conversion rates for US$
13.4 Research methodology
Exhibit 185: Research methodology
Exhibit 186: Validation techniques employed for market sizing
Exhibit 187: Information sources
13.5 List of abbreviations
Exhibit 188: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by End-user
Exhibits 6: Executive Summary - Chart on Market Segmentation by Type
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
Exhibits 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
Exhibits 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 18: Historic Market Size - Data Table on global breast cancer monoclonal antibodies market 2017 - 2021 ($ billion)
Exhibits 19: Historic Market Size - End-user Segment 2017 - 2021 ($ billion)
Exhibits 20: Historic Market Size - Type Segment 2017 - 2021 ($ billion)
Exhibits 21: Historic Market Size - Geography Segment 2017 - 2021 ($ billion)
Exhibits 22: Historic Market Size - Country Segment 2017 - 2021 ($ billion)
Exhibits 23: Five forces analysis - Comparison between 2022 and 2027
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits 26: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits 27: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits 28: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits 29: Chart on Market condition - Five forces 2022 and 2027
Exhibits 30: Chart on End-user - Market share 2022-2027 (%)
Exhibits 31: Data Table on End-user - Market share 2022-2027 (%)
Exhibits 32: Chart on Comparison by End-user
Exhibits 33: Data Table on Comparison by End-user
Exhibits 34: Chart on Hospitals - Market size and forecast 2022-2027 ($ billion)
Exhibits 35: Data Table on Hospitals - Market size and forecast 2022-2027 ($ billion)
Exhibits 36: Chart on Hospitals - Year-over-year growth 2022-2027 (%)
Exhibits 37: Data Table on Hospitals - Year-over-year growth 2022-2027 (%)
Exhibits 38: Chart on Research institutes - Market size and forecast 2022-2027 ($ billion)
Exhibits 39: Data Table on Research institutes - Market size and forecast 2022-2027 ($ billion)
Exhibits 40: Chart on Research institutes - Year-over-year growth 2022-2027 (%)
Exhibits 41: Data Table on Research institutes - Year-over-year growth 2022-2027 (%)
Exhibits 42: Chart on Others - Market size and forecast 2022-2027 ($ billion)
Exhibits 43: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
Exhibits 44: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibits 45: Data Table on Others - Year-over-year growth 2022-2027 (%)
Exhibits 46: Market opportunity by End-user ($ billion)
Exhibits 47: Data Table on Market opportunity by End-user ($ billion)
Exhibits 48: Chart on Type - Market share 2022-2027 (%)
Exhibits 49: Data Table on Type - Market share 2022-2027 (%)
Exhibits 50: Chart on Comparison by Type
Exhibits 51: Data Table on Comparison by Type
Exhibits 52: Chart on Humanized - Market size and forecast 2022-2027 ($ billion)
Exhibits 53: Data Table on Humanized - Market size and forecast 2022-2027 ($ billion)
Exhibits 54: Chart on Humanized - Year-over-year growth 2022-2027 (%)
Exhibits 55: Data Table on Humanized - Year-over-year growth 2022-2027 (%)
Exhibits 56: Chart on Human - Market size and forecast 2022-2027 ($ billion)
Exhibits 57: Data Table on Human - Market size and forecast 2022-2027 ($ billion)
Exhibits 58: Chart on Human - Year-over-year growth 2022-2027 (%)
Exhibits 59: Data Table on Human - Year-over-year growth 2022-2027 (%)
Exhibits 60: Chart on Chimeric - Market size and forecast 2022-2027 ($ billion)
Exhibits 61: Data Table on Chimeric - Market size and forecast 2022-2027 ($ billion)
Exhibits 62: Chart on Chimeric - Year-over-year growth 2022-2027 (%)
Exhibits 63: Data Table on Chimeric - Year-over-year growth 2022-2027 (%)
Exhibits 64: Chart on Murine - Market size and forecast 2022-2027 ($ billion)
Exhibits 65: Data Table on Murine - Market size and forecast 2022-2027 ($ billion)
Exhibits 66: Chart on Murine - Year-over-year growth 2022-2027 (%)
Exhibits 67: Data Table on Murine - Year-over-year growth 2022-2027 (%)
Exhibits 68: Market opportunity by Type ($ billion)
Exhibits 69: Data Table on Market opportunity by Type ($ billion)
Exhibits 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 71: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits 72: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits 73: Chart on Geographic comparison
Exhibits 74: Data Table on Geographic comparison
Exhibits 75: Chart on North America - Market size and forecast 2022-2027 ($ billion)
Exhibits 76: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
Exhibits 77: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibits 78: Data Table on North America - Year-over-year growth 2022-2027 (%)
Exhibits 79: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
Exhibits 80: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
Exhibits 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 83: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
Exhibits 84: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
Exhibits 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
Exhibits 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
Exhibits 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 91: Chart on US - Market size and forecast 2022-2027 ($ billion)
Exhibits 92: Data Table on US - Market size and forecast 2022-2027 ($ billion)
Exhibits 93: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibits 94: Data Table on US - Year-over-year growth 2022-2027 (%)
Exhibits 95: Chart on France - Market size and forecast 2022-2027 ($ billion)
Exhibits 96: Data Table on France - Market size and forecast 2022-2027 ($ billion)
Exhibits 97: Chart on France - Year-over-year growth 2022-2027 (%)
Exhibits 98: Data Table on France - Year-over-year growth 2022-2027 (%)
Exhibits 99: Chart on China - Market size and forecast 2022-2027 ($ billion)
Exhibits 100: Data Table on China - Market size and forecast 2022-2027 ($ billion)
Exhibits 101: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibits 102: Data Table on China - Year-over-year growth 2022-2027 (%)
Exhibits 103: Chart on The Netherlands - Market size and forecast 2022-2027 ($ billion)
Exhibits 104: Data Table on The Netherlands - Market size and forecast 2022-2027 ($ billion)
Exhibits 105: Chart on The Netherlands - Year-over-year growth 2022-2027 (%)
Exhibits 106: Data Table on The Netherlands - Year-over-year growth 2022-2027 (%)
Exhibits 107: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
Exhibits 108: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
Exhibits 109: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibits 110: Data Table on Canada - Year-over-year growth 2022-2027 (%)
Exhibits 111: Market opportunity By Geographical Landscape ($ billion)
Exhibits 112: Data Tables on Market opportunity By Geographical Landscape ($ billion)
Exhibits 113: Impact of drivers and challenges in 2022 and 2027
Exhibits 114: Overview on Criticality of inputs and Factors of differentiation
Exhibits 115: Overview on factors of disruption
Exhibits 116: Impact of key risks on business
Exhibits 117: Vendors covered
Exhibits 118: Matrix on vendor position and classification
Exhibits 119: Amgen Inc. - Overview
Exhibits 120: Amgen Inc. - Product/Service
Exhibits 121: Amgen Inc. - Key offerings
Exhibits 122: AstraZeneca Plc - Overview
Exhibits 123: AstraZeneca Plc - Product/Service
Exhibits 124: AstraZeneca Plc - Key news
Exhibits 125: AstraZeneca Plc - Key offerings
Exhibits 126: Boehringer Ingelheim International GmbH - Overview
Exhibits 127: Boehringer Ingelheim International GmbH - Business segments
Exhibits 128: Boehringer Ingelheim International GmbH - Key news
Exhibits 129: Boehringer Ingelheim International GmbH - Key offerings
Exhibits 130: Boehringer Ingelheim International GmbH - Segment focus
Exhibits 131: Bristol Myers Squibb Co. - Overview
Exhibits 132: Bristol Myers Squibb Co. - Product/Service
Exhibits 133: Bristol Myers Squibb Co. - Key news
Exhibits 134: Bristol Myers Squibb Co. - Key offerings
Exhibits 135: Celldex Therapeutics Inc. - Overview
Exhibits 136: Celldex Therapeutics Inc. - Product/Service
Exhibits 137: Celldex Therapeutics Inc. - Key offerings
Exhibits 138: Daiichi Sankyo Co. Ltd. - Overview
Exhibits 139: Daiichi Sankyo Co. Ltd. - Product/Service
Exhibits 140: Daiichi Sankyo Co. Ltd. - Key news
Exhibits 141: Daiichi Sankyo Co. Ltd. - Key offerings
Exhibits 142: F. Hoffmann La Roche Ltd. - Overview
Exhibits 143: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 144: F. Hoffmann La Roche Ltd. - Key news
Exhibits 145: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 146: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 147: Gilead Sciences Inc. - Overview
Exhibits 148: Gilead Sciences Inc. - Product/Service
Exhibits 149: Gilead Sciences Inc. - Key news
Exhibits 150: Gilead Sciences Inc. - Key offerings
Exhibits 151: Johnson and Johnson Services Inc. - Overview
Exhibits 152: Johnson and Johnson Services Inc. - Business segments
Exhibits 153: Johnson and Johnson Services Inc. - Key news
Exhibits 154: Johnson and Johnson Services Inc. - Key offerings
Exhibits 155: Johnson and Johnson Services Inc. - Segment focus
Exhibits 156: MacroGenics Inc. - Overview
Exhibits 157: MacroGenics Inc. - Product/Service
Exhibits 158: MacroGenics Inc. - Key offerings
Exhibits 159: Merck KGaA - Overview
Exhibits 160: Merck KGaA - Business segments
Exhibits 161: Merck KGaA - Key news
Exhibits 162: Merck KGaA - Key offerings
Exhibits 163: Merck KGaA - Segment focus
Exhibits 164: Novartis AG - Overview
Exhibits 165: Novartis AG - Business segments
Exhibits 166: Novartis AG - Key offerings
Exhibits 167: Novartis AG - Segment focus
Exhibits 168: Pfizer Inc. - Overview
Exhibits 169: Pfizer Inc. - Product/Service
Exhibits 170: Pfizer Inc. - Key news
Exhibits 171: Pfizer Inc. - Key offerings
Exhibits 172: Sanofi - Overview
Exhibits 173: Sanofi - Business segments
Exhibits 174: Sanofi - Key news
Exhibits 175: Sanofi - Key offerings
Exhibits 176: Sanofi - Segment focus
Exhibits 177: Viatris Inc. - Overview
Exhibits 178: Viatris Inc. - Business segments
Exhibits 179: Viatris Inc. - Key news
Exhibits 180: Viatris Inc. - Key offerings
Exhibits 181: Viatris Inc. - Segment focus
Exhibits 182: Inclusions checklist
Exhibits 183: Exclusions checklist
Exhibits 184: Currency conversion rates for US$
Exhibits 185: Research methodology
Exhibits 186: Validation techniques employed for market sizing
Exhibits 187: Information sources
Exhibits 188: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global breast cancer monoclonal antibodies market: Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celldex Therapeutics Inc., Celltrion Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Johnson and Johnson Services Inc., MacroGenics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Sanofi, Seagen Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increase in number of product approvals and expanded product pipeline.'

According to the report, one of the major drivers for this market is the increasing prevalence of breast cancer.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Celldex Therapeutics Inc.
  • Celltrion Co. Ltd.
  • Daiichi Sankyo Co. Ltd.
  • Eisai Co. Ltd.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • Johnson and Johnson Services Inc.
  • MacroGenics Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology Inc.
  • Sanofi
  • Seagen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Related Topics

Related Reports

Breast Cancer Liquid Biopsy Market 2024-2028 - Product Image

Breast Cancer Liquid Biopsy Market 2024-2028

  • Report
  • 141 Pages
  • Global
From
Breast Cancer Liquid Biopsy Testing Devices Market 2024-2028 - Product Image

Breast Cancer Liquid Biopsy Testing Devices Market 2024-2028

  • Report
  • 145 Pages
  • Global
From
Breast Cancer Monoclonal Antibodies Global Market Report 2024 - Product Image

Breast Cancer Monoclonal Antibodies Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease Area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) and Region - Forecast to 2028 - Product Image

Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease Area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) and Region - Forecast to 2028

  • Report
  • 307 Pages
  • Global
From
Metastatic Breast Cancer Treatment Global Market Report 2024 - Product Image

Metastatic Breast Cancer Treatment Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.